Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1R,2S-Milnacipran SCHEMBL30083111 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL12027608 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1707471 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL5504533 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1414867 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL8099 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL1156056 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL4434769 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL16241424 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1289763 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362824-B | Process for the preparation of 2- (aminomethyl) -N, N-diethyl-1-phenylcyclopropanecarboxamide and salts thereof | 四川科瑞德制药股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| US-11497739-B2 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-11-15 | — | — | US | claimed |
| WO-2014203277-A2 | PROCESS FOR THE PREPARATION OF (1S,2R)-2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYLCYCLOPROPANEARBOXAMIDE HYDROCHLORIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| US-20130253063-A1 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2013-09-26 | — | — | US | claimed |
| WO-2012046247-A2 | PROCESS FOR THE PREPARATION OF (±M1R(S), 2SRR)L-2-(AMINOMETHYL)-N,N-DIETHYL-L-PHENYLCYCLOPROPANE CARBOXAMIDE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | claimed |
| EP-1908461-B9 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PF MEDICAMENT (FR) | 2011-08-31 | — | — | EP | claimed |
| EP-1770084-B1 | METHOD FOR PRODUCING (Z)-1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYL CYCLOPROPANE HYDROCHLORIDE | SUMITOMO CHEMICAL CO (JP) | 2011-08-24 | — | — | EP | claimed |
| US-7943785-B2 | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2- phthalimidomethylcyclopropane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | claimed |
| EP-1845084-B1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)IDOMETHYLCYCLOPROPANE | SUMITOMO CHEMICAL CO (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-1908461-B1 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PF MEDICAMENT (FR) | 2011-03-16 | — | — | EP | claimed |
| EP-1770084-A1 | METHOD FOR PRODUCING (Z)-1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYL CYCLOPROPANE HYDROCHLORIDE | Sumitomo Chemical Company, Limited (JP) | 2007-04-04 | — | — | EP | claimed |
| US-7074833-B2 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2006-07-11 | — | — | US | claimed |
| US-20060014837-A1 | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1601349-A1 | USE OF THE ENANTIOMER (1S, 2R) OF MILNACIPRAN FOR THE PREPARATION OF A MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2005-12-07 | — | — | EP | claimed |
| US-20040259953-A1 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2004-12-23 | — | — | US | claimed |
| WO-2004075886-A1 | USE OF THE ENANTIOMER (1S, 2R) OF MILNACIPRAN FOR THE PREPARATION OF A MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2004-09-10 | — | — | WO | claimed |
| US-20040162334-A1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2004-08-19 | — | — | US | claimed |
| EP-0200638-B1 | PROCESS FOR THE PREPARATION OF (Z)-1-PHENYL-1-DIETHYL AMINO CARBONYL 2-AMINO METHYL CYCLOPROPANE HYDROCHLORIDE | PIERRE FABRE MEDICAMENT (FR) | 1989-04-19 | — | — | EP | claimed |
| EP-0068999-B1 | DERIVATIVES OF 1-ARYL-2-AMINOMETHYL-CYCLOPROPANE-CARBOXAMIDES (Z), THEIR PREPARATION AND THEIR USE AS MEDICINES IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | PIERRE FABRE S.A. (FR) | 1985-05-22 | — | — | EP | claimed |
| US-4478836-A | 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system | PIERRE FABRE S.A. (FR) | 1984-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014837-A1 | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug | SLC6A2, ADRA1D, HTR3A | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 20/4885 |
| US-11497739-B2 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation | APP, BACE1, BDNF | SLC6A2 39/4885SLC6A4 115/4885SLC6A3 35/4885 |
| US-20040259953-A1 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug | SLC6A2, ADRA1D, HTR3A | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 20/4885 |
| US-20130253063-A1 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN | LPXN, TNNC1, TNNI3 | SLC6A2 33/4885SLC6A4 4/4885SLC6A3 91/4885 |
| US-20040162334-A1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | SLC6A4, SLC6A2, HTR6 | SLC6A2 2/4885SLC6A4 1/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.